We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas.
- Authors
von Mehren, Margaret; Rankin, Cathryn; Goldblum, John R; Demetri, George D; Bramwell, Vivien; Ryan, Christopher W; Borden, Ernest
- Abstract
Patients with advanced soft tissue sarcomas (STS) have limited therapeutic options. Sorafenib (BAY 43-9006) is a multitargeted tyrosine kinase inhibitor of raf, vascular endothelial growth factor receptors 1 (VEGFR1) through 3, platelet-derived growth factor B, fms-like tyrosine kinase 3, and c-kit, and some of these may be relevant in STS.
- Publication
Cancer, 2012, Vol 118, Issue 3, p770
- ISSN
1097-0142
- Publication type
Journal Article
- DOI
10.1002/cncr.26334